Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies

doi:10.5306/wjco.v3.i7.111

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 7

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2647)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

317

HTML

2204

Figures (1-1)

126

Sum=2647

Jul 10, 2012 (publication date) through May 18, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Oncol. Jul 10, 2012; 3(7): 111-115
Published online Jul 10, 2012. doi: 10.5306/wjco.v3.i7.111

Full Size Figure Download Figure

Figure 1 The marked decrease in fluoro-2-deoxy-D-glucose uptake in positron emission tomography/computed tomography performed in October, 2010 (below) in comparison to positron emission tomography/computed tomography performed in August, 2010 (above) in patient 1. Color scales are approximately the same.

Citation: Palmieri G, Buonerba C, Federico P, Formisano L, Nappi L, Lorenzo GD, Marino M, Damiano V. Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies. World J Clin Oncol 2012; 3(7): 111-115
URL: https://www.wjgnet.com/2218-4333/full/v3/i7/111.htm
DOI: https://dx.doi.org/10.5306/wjco.v3.i7.111